Year in Review: Melanoma

Year in Review: Melanoma

After several years of exciting developments in melanoma therapy, progress continued throughout 2015 with FDA approved PD-1 immunotherapy treatments and the first-ever approved oncolytic virus therapy drug, Imlygic. Also noteworthy for those with advanced melanoma, a promising new combination treatment which includes an imiquimod/topical therapy has been found to be highly effective in treating patients with skin metastases. The results have been so encouraging that there will most likely be more news on this topic as 2016 progresses.

CancerConnect News coverage of advances in the management of melanoma included the following key developments in 2015:

2015 FDA News

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma

Imlygic® Approved for Melanoma

MRA Hails FDA Approval of First Combination Immunotherapy for Melanoma

2015 Melanoma Research News

New Combination Treatment Effective Against Melanoma Skin Metastases

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma

Melanoma Drug T-VEC Receives Recommendation for FDA Approval

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma

Yervoy® Improves Treatment of Stage III Melanoma

Other 2015 Melanoma News

Coffee May Decrease Risk of Melanoma Skin Cancer

Moffitt Researchers Discover Mechanism Leading to Drug Resistance, Metastasis in Melanoma Patients



Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey?

  • Sign up for monthly newsletters on melanoma here.
  • Get the facts about melanoma here.
  • Join ongoing discussions with other individuals affected by melanoma in the CancerConnect private online support group here.
  • Follow CancerConnect on Facebook and Twitter.

Copyright © 2018 CancerConnect. All Rights Reserved.